Literature DB >> 300075

Murine sarcoma virus (MSV)-induced tumors in mice. I. Distribution of MSV-immune cytolytic T lymphocytes in vivo.

F Plata, B Sordat.   

Abstract

Quantitative studies using a 51Cr release assay were performed to analyse the time-course of appearance and specificity of cytolytic cells in C57Bl/6 mice inoculated with Moloney murine sarcoma virus (MSV). Various lymphoid organs were studied including spleen, mesenteric lymph nodes (MLN), lymph nodes regional to the MSV-induced tumor (RLN), and peripheral blood. Furthermore, the kinetics of appearance of cytolytic cells within the MSV-induced tumor was determined. In agreement with previous studied, it was found that cytolytic T lymphocytes (CTL) specific for MSV-associated antigens were present among the cells extracted from the tumor and from the lymphoid organs. However, differences in the kinetics of CTL activity could be documented: lymphoid cells from spleen, RLN and peripheral blood showed peak activity at the time of maximum tumor diameter, while intratumoral cells showed peak activity at the onset of tumor regression. MLN cells showed cytolytic activity only when tumor regression had begun. Naturally cytotoxic cell populations of thymus-independent origin, present in normal control mice, were also detected in MSV-infected mice.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300075     DOI: 10.1002/ijc.2910190210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Bistability in fluctuating environments. Implications in tumor immunology.

Authors:  R Lefever; W Horsthemke
Journal:  Bull Math Biol       Date:  1979       Impact factor: 1.758

3.  Use of hybridoma-resident variant cell lines to study H-2Db/FMR-specific cytotoxic T cells.

Authors:  J M Chapdelaine; T V Rajan; S G Nathenson; F Lilly
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

4.  Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.

Authors:  D Characiejus; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 5.  Immune surveillance and natural resistance: an evaluation.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.

Authors:  T L Knisely; J Y Niederkorn
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes.

Authors:  J M Chapdelaine; F Plata; F Lilly
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

8.  Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens.

Authors:  A Weiss; K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

9.  Specificity studies on cytolytic T lymphocytes directed against murine leukemia virus-induced tumors. Analysis of monoclonal cytolytic T lymphocytes.

Authors:  F Plata
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

10.  Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors.

Authors:  K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.